OncoGenex

OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.
Company Growth (employees)
Type
Public
HQ
Bothell, US
Size (employees)
17 (est)
OncoGenex is headquartered in Bothell, US

Key People/Management at OncoGenex

Scott Cormack

Scott Cormack

President & Chief Executive Officer
David V. Smith

David V. Smith

Director

OncoGenex Office Locations

OncoGenex has offices in Bothell and Vancouver
Bothell, US (HQ)
201 19820 North Creek Pkwy
Vancouver, CA
400 1001 W Broadway

OncoGenex Financials and Metrics

OncoGenex Financials

USD

Net income (Q2, 2017)

(3 m)

Market capitalization (13-Dec-2017)

3.4 m

Cash (30-Jun-2017)

13.9 m
OncoGenex's current market capitalization is $3.4 m.
USDFY, 2013FY, 2016

R&D expense

14.8 m

General and administrative expense

8.9 m

Operating expense total

23.7 m

EBIT

(28.4 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

18 m16.9 m9.9 m9.6 m3.7 m6.5 m8.3 m4.6 m4.7 m3.8 m912 k777 k

General and administrative expense

2.5 m2.8 m2.7 m2.5 m2.7 m3.1 m3.1 m2.3 m2.5 m1.9 m2.5 m2.3 m

Operating expense total

20.5 m19.7 m12.6 m12 m6.4 m9.6 m11.4 m7.4 m8.5 m4.4 m3.3 m3.1 m

Interest income

33 k12 k4 k3 k54 k13 k24 k48 k61 k53 k27 k23 k
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

14.6 m27.9 m34.3 m15.2 m

Accounts Receivable

218 k113 k111 k32 k

Current Assets

53.9 m55.8 m57.3 m26.9 m

PP&E

397 k257 k602 k258 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

13 m28.6 m40.6 m49 m25.3 m48 m42.5 m18.9 m10.6 m11.8 m15.7 m13.9 m

Accounts Receivable

295 k166 k19 k71 k76 k48 k53 k47 k36 k32 k32 k

Current Assets

59.7 m48.1 m47.9 m61.3 m45.5 m62.7 m67.6 m48 m41.4 m34.3 m17.5 m14.5 m

PP&E

443 k349 k354 k312 k416 k406 k380 k546 k534 k493 k166 k129 k
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(31.8 m)(26.2 m)(16.8 m)(20.1 m)

Depreciation and Amortization

227 k223 k244 k188 k

Accounts Receivable

109 k105 k2 k79 k

Accounts Payable

(1.2 m)(67 k)1.3 m778 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(25.2 m)(8.6 m)(15.7 m)(20.6 m)(4.5 m)(10.5 m)(15.1 m)(3.7 m)(10.6 m)(14.3 m)(3.3 m)(6.3 m)

Depreciation and Amortization

162 k55 k110 k165 k46 k116 k178 k56 k103 k148 k93 k130 k

Accounts Receivable

32 k52 k218 k199 k42 k37 k65 k58 k64 k75 k32 k32 k

Accounts Payable

(1.3 m)784 k1.2 m1.4 m916 k230 k1.7 m(751 k)(784 k)(300 k)(1.8 m)(1.9 m)
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

OncoGenex Market Value History

OncoGenex's Web-traffic and Trends

OncoGenex Online and Social Media Presence

OncoGenex Company Life and Culture

You may also be interested in